Glucotrack's Implantable Glucose Monitor Achieves 6.8% MARD in Peer-Reviewed Study, Bolstering FDA Path
GCTK sits 26% above its 52-week low of $0.619 on elevated volume (33× avg).
Summary
Glucotrack announced the publication of a peer-reviewed study in The Journal of Diabetes Research, demonstrating the long-term accuracy and stability of its fully implantable continuous blood glucose monitoring (CBGM) system. The in-vivo ovine study showed a weighted average Mean Absolute Relative Difference (MARD) of 6.8% over 240 days, with no device-related adverse safety events. This external validation significantly de-risks the company's core technology and provides crucial support for its upcoming Investigational Device Exemption (IDE) submission to the FDA. For a development-stage medical technology company, strong preclinical data published in a peer-reviewed journal is a material step towards clinical development and eventual commercialization. Investors will now focus on the timing and outcome of the FDA IDE submission and the initiation of human clinical trials.
At the time of this announcement, GCTK was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $0.62 to $15.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.